HC Wainwright Reaffirms Buy Rating for Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Pharmaceuticals (NASDAQ:RVPH)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report issued on Thursday, Benzinga reports. They currently have a $14.00 price objective on the stock.

Separately, Benchmark reissued a “speculative buy” rating and set a $17.00 price target on shares of Reviva Pharmaceuticals in a research report on Tuesday, May 28th.

Reviva Pharmaceuticals Price Performance

NASDAQ RVPH opened at $1.37 on Thursday. The company has a market cap of $38.25 million, a price-to-earnings ratio of -0.86 and a beta of -0.09. The stock’s fifty day moving average price is $2.22 and its 200 day moving average price is $3.37. Reviva Pharmaceuticals has a 1 year low of $1.21 and a 1 year high of $6.80.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.03. Research analysts expect that Reviva Pharmaceuticals will post -0.98 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Vontobel Holding Ltd. acquired a new position in Reviva Pharmaceuticals in the 4th quarter worth about $72,000. Vanguard Group Inc. increased its position in shares of Reviva Pharmaceuticals by 2.8% in the first quarter. Vanguard Group Inc. now owns 1,001,836 shares of the company’s stock valued at $3,787,000 after buying an additional 26,854 shares in the last quarter. Finally, Armistice Capital LLC raised its stake in shares of Reviva Pharmaceuticals by 194.0% during the 4th quarter. Armistice Capital LLC now owns 1,764,000 shares of the company’s stock worth $9,085,000 after buying an additional 1,164,000 shares during the period. Institutional investors and hedge funds own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.